22 mg) of buprenorphine to the combination product, dose adjustments may be necessary especially in the later phase of the treatment. We recommend that a transfer from Subutex to Suboxone should be carefully discussed and planned in advance with the patients and after the transfer adverse events should be regularly monitored. With regard of buprenorphine IV abuse, the combination product seems to have a less abuse potential than buprenorphine alone."/>
Skip to main content

Table 3 Maintenance dose weeks 1–4 (n = 64)

From: A retrospective evaluation of patients switched from buprenorphine (subutex) to the buprenorphine/naloxone combination (suboxone)

  n (%)
Treated with Suboxone only throughout 4-week study period 53 (82.8)
Stayed at same dose of Suboxone only throughout 4-week study period 46 (71.9)
Dose reduction 4 (6.3)
Dose increase 1 (1.1)
Temporary dose change 2 (3.1)
Titrated1 with Subutex throughout 4-week study period 7 (11)
Discontinued treatment with Suboxone during 4-week study period 4 (6.2)
  1. 1patients had at the same time Suboxone and Subutex, first day 50:50 and during the first week gradually to Suboxone only